



## Clinical trial results:

### A Phase III, Double-Blind, Placebo-Controlled, Randomized Study of Taselisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor-Positive And Her2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatases Inhibitor Therapy

#### Summary

EudraCT number	2014-003185-25
Trial protocol	IT PT ES CZ DE AT NL PL BG FR SE GR RO FI
Global end of trial date	29 June 2021

#### Results information

Result version number	v2 (current)
This version publication date	29 June 2022
First version publication date	19 June 2019
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	GO29058
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02340221
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, +41 616878333, global.trial_information@roche.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 June 2021
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	29 June 2021
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this study was to compare the efficacy between taseleisib + fulvestrant versus placebo + fulvestrant as measured by investigator-assessed progression-free survival (PFS) in postmenopausal women with estrogen receptor-positive and human epidermal receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with phosphatidylinositol-4,5-bisphosphate 3-kinase (PIK3CA)-mutant tumors, who had disease recurrence or progression during or after aromatase inhibitor therapy.

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	09 April 2015
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	3 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 35
Country: Number of subjects enrolled	Austria: 9
Country: Number of subjects enrolled	Bulgaria: 22
Country: Number of subjects enrolled	Bosnia and Herzegovina: 1
Country: Number of subjects enrolled	Canada: 64
Country: Number of subjects enrolled	China: 21
Country: Number of subjects enrolled	Colombia: 4
Country: Number of subjects enrolled	Czechia: 4
Country: Number of subjects enrolled	Germany: 9
Country: Number of subjects enrolled	Spain: 49
Country: Number of subjects enrolled	Finland: 2
Country: Number of subjects enrolled	France: 32
Country: Number of subjects enrolled	Greece: 12
Country: Number of subjects enrolled	Italy: 40
Country: Number of subjects enrolled	Korea, Republic of: 60
Country: Number of subjects enrolled	Mexico: 32
Country: Number of subjects enrolled	Netherlands: 4

Country: Number of subjects enrolled	Peru: 20
Country: Number of subjects enrolled	Poland: 44
Country: Number of subjects enrolled	Portugal: 23
Country: Number of subjects enrolled	Romania: 30
Country: Number of subjects enrolled	Russian Federation: 23
Country: Number of subjects enrolled	Serbia: 10
Country: Number of subjects enrolled	Sweden: 3
Country: Number of subjects enrolled	Thailand: 5
Country: Number of subjects enrolled	Turkey: 20
Country: Number of subjects enrolled	Taiwan: 10
Country: Number of subjects enrolled	United States: 43
Worldwide total number of subjects	631
EEA total number of subjects	283

Notes:

---

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	430
From 65 to 84 years	198
85 years and over	3

## Subject disposition

### Recruitment

Recruitment details:

This study was conducted at 155 centers in 28 countries.

### Pre-assignment

Screening details:

The study enrolled postmenopausal women with estrogen receptor-positive and HER2-negative locally advanced or metastatic breast cancer. Randomisation was stratified by three factors: 1) visceral versus non-visceral disease, 2) sensitivity versus non-sensitivity to most recent endocrine therapy, and 3) geographical region.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo+Fulvestrant

Arm description:

Subjects received taselisib-matching placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received taselisib-matching placebo orally QD beginning at Cycle 1, Day 1 until disease progression, unacceptable toxicity, or study termination by the Sponsor.

Investigational medicinal product name	Fulvestrant
Investigational medicinal product code	
Other name	Faslodex
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects received fulvestrant 500 mg IM injection on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.

<b>Arm title</b>	Taselisib+Fulvestrant
------------------	-----------------------

Arm description:

Subjects received taselisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Taselisib
Investigational medicinal product code	RO5537381
Other name	GDC-0032
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received taselisib 4 mg orally QD beginning at Cycle 1, Day 1 until disease progression, unacceptable toxicity, or study termination by the Sponsor.

Investigational medicinal product name	Fulvestrant
Investigational medicinal product code	
Other name	Faslodex
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects received fulvestrant 500 mg IM injection on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.

<b>Number of subjects in period 1</b>	Placebo+Fulvestrant	Taselisib+Fulvestrant
Started	214	417
Completed	0	0
Not completed	214	417
Death	100	197
Reason Not Specified	85	165
Withdrawal by Subject	24	37
Study Terminated by Sponsor	1	3
Lost to follow-up	4	15

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo+Fulvestrant
Reporting group description:	
Subjects received taselisib-matching placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.	
Reporting group title	Taselisib+Fulvestrant
Reporting group description:	
Subjects received taselisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.	

Reporting group values	Placebo+Fulvestrant	Taselisib+Fulvestrant	Total
Number of subjects	214	417	631
Age categorical Units: Subjects			
Age Continuous Units: years arithmetic mean standard deviation	60.7 ± 10.0	60.1 ± 9.9	-
Sex: Female, Male Units: Subjects			
Female	214	417	631
Male	0	0	0

## End points

### End points reporting groups

Reporting group title	Placebo+Fulvestrant
Reporting group description: Subjects received taselisib-matching placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.	
Reporting group title	Taselisib+Fulvestrant
Reporting group description: Subjects received taselisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.	

### Primary: Progression-Free Survival (PFS) in Subjects with PIK3CA-mutant Tumours as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) at Primary Analysis

End point title	Progression-Free Survival (PFS) in Subjects with PIK3CA-mutant Tumours as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) at Primary Analysis
End point description: PFS was defined as the time from randomisation to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimetres (mm). For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression. Randomised subjects with PIK3CA-mutant tumors, regardless of whether they received any amount of study treatment. Number of subjects analysed is the number of subjects with data available for analysis at given time point.	
End point type	Primary
End point timeframe: From randomisation until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)	

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	340		
Units: months				
median (confidence interval 95%)	5.39 (3.68 to 7.29)	7.43 (7.26 to 9.07)		

### Statistical analyses

Statistical analysis title	Taselisib+Fulvestrant vs Placebo+Fulvestrant
Comparison groups	Placebo+Fulvestrant v Taselisib+Fulvestrant

Number of subjects included in analysis	516
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0037
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	0.89

### Primary: PFS in Subjects with PIK3CA-mutant Tumours as Assessed by Investigator Using RECIST v1.1 at Final Analysis

End point title	PFS in Subjects with PIK3CA-mutant Tumours as Assessed by Investigator Using RECIST v1.1 at Final Analysis
-----------------	--

#### End point description:

PFS was defined as the time from randomisation to disease progression as determined by the investigator with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression. Randomised subjects with PIK3CA-mutant tumors, regardless of whether they received any amount of study treatment. Number of subjects analysed is the number of subjects with data available for analysis at given time point.

End point type	Primary
----------------	---------

#### End point timeframe:

From randomisation until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years)

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	340		
Units: months				
median (confidence interval 95%)	5.55 (3.75 to 7.33)	8.05 (7.33 to 9.10)		

### Statistical analyses

Statistical analysis title	Taselisib+Fulvestrant vs Placebo+Fulvestrant
Comparison groups	Placebo+Fulvestrant v Taselisib+Fulvestrant



Number of subjects included in analysis	516
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0008
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.58
upper limit	0.87

### Secondary: Percentage of Subjects with Objective Response (Partial Response [PR] plus Complete Response [CR]), as Assessed Using RECIST v.1.1 at Primary Analysis

End point title	Percentage of Subjects with Objective Response (Partial Response [PR] plus Complete Response [CR]), as Assessed Using RECIST v.1.1 at Primary Analysis
-----------------	--

End point description:

PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalisation of tumor marker levels (as applicable to non-target lesions). Randomised subjects with PIK3CA-mutant tumors and measurable disease at baseline, regardless of whether they received any amount of study treatment. Number of subjects analysed is the number of subjects with data available for analysis at given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomisation until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134	264		
Units: percentage of subjects				
number (confidence interval 95%)	11.9 (7.1 to 18.3)	28.0 (22.7 to 33.8)		

### Statistical analyses

Statistical analysis title	Taselisib+Fulvestrant vs Placebo+Fulvestrant
Comparison groups	Placebo+Fulvestrant v Taselisib+Fulvestrant

Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	3
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.6
upper limit	5.4

## Secondary: Overall Survival (OS) at Primary Analysis

End point title	Overall Survival (OS) at Primary Analysis
End point description:	OS was defined as the time from the date of randomisation to the date of death due to any cause. Randomised subjects with PIK3CA-mutant tumors, regardless of whether they received any amount of study treatment. Number of subjects analysed is the number of subjects with data available for analysis at given time point. 99999 represents that the upper limit of confidence interval was not estimable due to the low number of subjects with events.
End point type	Secondary
End point timeframe:	From randomisation up to death from any cause (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	340		
Units: months				
median (confidence interval 95%)	23.56 (18.00 to 99999)	26.81 (21.29 to 99999)		

## Statistical analyses

Statistical analysis title	Taselisib+Fulvestrant vs Placebo+Fulvestrant
Comparison groups	Placebo+Fulvestrant v Taselisib+Fulvestrant
Number of subjects included in analysis	516
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4151
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.85

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.58
upper limit	1.25

## Secondary: Percentage of Subjects with Clinical Benefit, as Assessed According to RECIST v1.1 at Primary Analysis

End point title	Percentage of Subjects with Clinical Benefit, as Assessed According to RECIST v1.1 at Primary Analysis
-----------------	--

### End point description:

Clinical benefit:objective response (PR+CR),or no disease progression lasting for more than or equal to (>/=) 24 weeks since randomisation.PR:at least a 30% decrease in sum of diameters of target lesions,taking as reference baseline sum of diameters.CR:disappearance of all target and non-target lesions and normalisation of tumor marker levels.Disease progression:at least a 20% increase in sum of diameters of target lesions,taking as reference smallest sum on study,including baseline.In addition to relative increase of 20%,sum must also demonstrate absolute increase of at least 5 mm.For non-target lesions,disease progression:unequivocal progression of existing lesions.Appearance of one or more new lesions was also considered progression.Randomised subjects with PIK3CA-mutant tumors and measurable disease at baseline,regardless of whether they received any amount of study treatment.Number of subjects analysed is number of subjects with data available at given time point.

End point type	Secondary
----------------	-----------

### End point timeframe:

From randomisation until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134	264		
Units: percentage of subjects				
number (confidence interval 95%)	37.3 (29.1 to 45.7)	51.5 (45.3 to 57.7)		

## Statistical analyses

Statistical analysis title	Taselisib+Fulvestrant vs Placebo+Fulvestrant
Comparison groups	Placebo+Fulvestrant v Taselisib+Fulvestrant
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.2
upper limit	2.9

## Secondary: Duration of Objective Response (DOR), as Assessed by Investigator Using RECIST v1.1 at Primary Analysis

End point title	Duration of Objective Response (DOR), as Assessed by Investigator Using RECIST v1.1 at Primary Analysis
-----------------	---

### End point description:

DOR:time from first tumor assessment for objective response to first documented disease progression or death due to any cause, whichever occurred first. CR:disappearance of all target and non-target lesions and normalisation of tumor marker levels.PR:at least a 30% decrease in the sum of diameters of target lesions,taking as reference baseline sum of diameters. Disease progression:at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline.For non-target lesions, disease progression:unequivocal progression of existing lesions.Appearance of one or more new lesions was also considered progression.Randomised subjects with PIK3CA-mutant tumors and measurable disease at baseline, regardless of whether they received any amount of study treatment. Number analysed:number of subjects with data available for analysis at given timepoint. 99999=upper limit of CI was not estimable due to low number of subjects with events.

End point type	Secondary
----------------	-----------

### End point timeframe:

Time from the first occurrence of a documented objective response to the time of the first documented disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	16	74		
Units: months				
median (confidence interval 95%)	7.23 (6.51 to 99999)	8.74 (5.72 to 11.24)		

## Statistical analyses

Statistical analysis title	Taselisib+Fulvestrant vs Placebo+Fulvestrant
Comparison groups	Placebo+Fulvestrant v Taselisib+Fulvestrant
Number of subjects included in analysis	90
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6708
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.23
upper limit	2.59

## Secondary: PFS as Assessed by Blinded Independent Central Review (BICR) Using RECIST v1.1 at Primary Analysis

End point title	PFS as Assessed by Blinded Independent Central Review (BICR) Using RECIST v1.1 at Primary Analysis
-----------------	--

### End point description:

PFS was defined as the time from randomisation to disease progression as determined by BICR with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression. Randomised subjects with PIK3CA-mutant tumors, regardless of whether they received any amount of study treatment. Number of subjects analysed is the number of subjects with data available for analysis at given time point.

End point type	Secondary
----------------	-----------

### End point timeframe:

From randomisation until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to the 15 Oct 2017 data cutoff, approximately 2.5 years)

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	340		
Units: months				
median (confidence interval 95%)	5.39 (3.68 to 9.23)	8.97 (7.39 to 9.49)		

## Statistical analyses

Statistical analysis title	Taselisib+Fulvestrant vs Placebo+Fulvestrant
Comparison groups	Placebo+Fulvestrant v Taselisib+Fulvestrant
Number of subjects included in analysis	516
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0023
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.51
upper limit	0.86

## Secondary: Percentage of Subjects with Adverse Events (AEs) at Primary Analysis

End point title	Percentage of Subjects with Adverse Events (AEs) at Primary Analysis
-----------------	--

End point description:

An adverse event (AE) was any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The safety-evaluable population included all randomised subjects who received at least one dose of taselisib or placebo or fulvestrant. Number of subjects analysed is the number of subjects with data available for analysis at given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomisation up to the 15 Oct 2017 data cutoff, approximately 2.5 years

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213	416		
Units: percentage of subjects				
number (not applicable)	89.7	95.4		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maximum Observed Plasma Concentration (Cmax) of Taselisib

End point title	Maximum Observed Plasma Concentration (Cmax) of
-----------------	---

End point description:

The Pharmacokinetic (PK) population included all subjects who received at least one dose of taselisib and provided valid (adequately documented dose time and PK sample time) PK assessments. "n" is the number of subjects with data available for analysis at given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

1 to 4 hours (hrs) post-dose on Cycle (C) 1, Day (D) 1; 0 to 3 hrs pre-dose and 2 to 6 hrs post dose on Cycle 2, Day 1 (each cycle=28 days)

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Results are reported only for the taselisib treatment arm.

End point values	Taselisib+Fulvestrant			
Subject group type	Reporting group			
Number of subjects analysed	417			
Units: ng/mL				
arithmetic mean (standard deviation)				
C1D1 (n= 391)	18.2 (± 14.6)			
C2D1 (n=359)	66.6 (± 35.2)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Minimum Observed Plasma Concentration (Cmin) of Taselisib

End point title	Minimum Observed Plasma Concentration (Cmin) of Taselisib <sup>[2]</sup>
-----------------	--

End point description:

The PK population included all subjects who received at least one dose of taselisib and provided valid (adequately documented dose time and PK sample time) PK assessments. "n" is the number of subjects with data available for analysis at given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

1 to 4 hrs post-dose on Cycle 1, Day 1; 0 to 3 hrs pre-dose and 2 to 6 hrs post dose on Cycle 2, Day 1; 0 to 3 hrs pre-dose on Cycle 6, Day 1 (each cycle=28 days)

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Results are reported only for the taselisib treatment arm.

End point values	Taselisib+Fulvestrant			
Subject group type	Reporting group			
Number of subjects analysed	417			
Units: ng/mL				
arithmetic mean (standard deviation)				
C2D1 (n=377)	42.8 (± 26.6)			
C6D1 (n=213)	35.3 (± 31.5)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) Score

End point title	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) Score
-----------------	--

End point description:

The EORTC QLQ-C30 consists of 30 questions that comprise aspects of subject's functioning assessment (physical, emotional, role, cognitive, and social); symptom scales (fatigue; nausea, vomiting, and pain; the global health/quality of life [QoL]); and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties), within a recall period of "the past week." Most questions used a 4-point scale (1=Not at all to 4=Very much; two questions used a 7-point scale (1=Very poor to 7=Excellent). Scores were averaged and transformed to a 0-100 scale; a higher score for Global QoL/functional scales=better level of functioning; a higher score for symptom scale=greater degree of symptoms. Randomised subjects with PIK3CA-mutant tumors, regardless of whether they received any amount of study treatment. "n" is the number of subjects with data available for analysis

at given time point.

End point type	Secondary
End point timeframe:	
Baseline, C2D1 up to C7D1 (each cycle=28 days)	

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	340		
Units: score on a scale				
arithmetic mean (standard deviation)				
Appetite Loss: Baseline (n=159, 312)	15.9 (± 25.9)	15.3 (± 23.3)		
Appetite Loss: Change at C2D1 (n=147, 292)	-0.2 (± 25.7)	6.2 (± 26.2)		
Appetite Loss: Change at C3D1 (n=117, 260)	-4.3 (± 27.2)	8.7 (± 28.1)		
Appetite Loss: Change at C4D1 (n=100, 231)	-1.7 (± 26.1)	8.4 (± 28.1)		
Appetite Loss: Change at C5D1 (n=75, 206)	-0.4 (± 26.6)	6.0 (± 27.2)		
Appetite Loss: Change at C6D1 (n=66, 171)	-0.5 (± 22.3)	6.6 (± 27.2)		
Appetite Loss: Change at C7D1 (n=58, 145)	-5.7 (± 28.7)	4.6 (± 26.5)		
Cognitive Functioning: Baseline (n=160, 312)	85.3 (± 18.1)	85.9 (± 18.7)		
Cognitive Functioning: Change at C2D1 (n=147, 292)	0.7 (± 16.5)	-1.1 (± 16.8)		
Cognitive Functioning: Change at C3D1 (n=117, 260)	0.9 (± 17.9)	-2.9 (± 19.1)		
Cognitive Functioning: Change at C4D1 (n=100, 231)	1.8 (± 18.9)	-1.7 (± 18.4)		
Cognitive Functioning: Change at C5D1 (n=76, 207)	-1.5 (± 17.7)	-3.2 (± 17.7)		
Cognitive Functioning: Change at C6D1 (n=66, 171)	-0.5 (± 18.5)	-2.8 (± 17.6)		
Cognitive Functioning: Change at C7D1 (n=58, 145)	-2.3 (± 18.1)	-0.8 (± 18.8)		
Constipation: Baseline (n=160, 312)	15.8 (± 23.9)	14.5 (± 23.7)		
Constipation: Change at C2D1 (n=147, 291)	0.0 (± 24.0)	-6.0 (± 21.1)		
Constipation: Change at C3D1 (n=117, 260)	-2.3 (± 25.0)	-4.9 (± 20.8)		
Constipation: Change at C4D1 (n=99, 231)	-2.7 (± 24.6)	-5.5 (± 22.0)		
Constipation: Change at C5D1 (n=76, 207)	-1.3 (± 22.7)	-4.0 (± 21.0)		
Constipation: Change at C6D1 (n=66, 170)	-3.0 (± 27.3)	-3.5 (± 21.8)		
Constipation: Change at C7D1 (n=58, 145)	-4.6 (± 24.5)	-6.9 (± 22.5)		
Diarrhoea: Baseline (n=159, 311)	6.3 (± 15.1)	5.0 (± 14.4)		
Diarrhoea: Change at C2D1 (n=147, 292)	-0.5 (± 17.9)	10.2 (± 22.4)		
Diarrhoea: Change at C3D1 (n=117, 260)	-0.9 (± 16.6)	13.7 (± 26.3)		



Diarrhoea: Change at C4D1 (n=100, 231)	-2.7 (± 21.0)	13.1 (± 28.9)		
Diarrhoea: Change at C5D1 (n=76, 207)	-2.6 (± 19.4)	11.1 (± 27.7)		
Diarrhoea: Change at C6D1 (n=66, 171)	-2.0 (± 17.4)	14.0 (± 29.1)		
Diarrhoea: Change at C7D1 (n=58, 145)	1.1 (± 20.7)	15.6 (± 30.9)		
Dyspnoea: Baseline (n=160, 311)	15.0 (± 23.0)	15.4 (± 22.2)		
Dyspnoea: Change at C2D1 (n=146, 291)	4.1 (± 23.5)	-2.1 (± 19.5)		
Dyspnoea: Change at C3D1 (n=117, 260)	2.8 (± 20.3)	0.0 (± 20.9)		
Dyspnoea: Change at C4D1 (n=100, 231)	0.7 (± 23.2)	0.0 (± 23.3)		
Dyspnoea: Change at C5D1 (n=76, 207)	2.6 (± 26.5)	1.6 (± 23.2)		
Dyspnoea: Change at C6D1 (n=66, 170)	3.0 (± 26.6)	0.2 (± 23.4)		
Dyspnoea: Change at C7D1 (n=58, 145)	1.7 (± 24.5)	-2.1 (± 21.2)		
Emotional Functioning: Baseline (n=160, 312)	73.1 (± 22.1)	71.9 (± 22.1)		
Emotional Functioning: Change at C2D1 (n=147, 292)	4.0 (± 17.9)	5.1 (± 18.5)		
Emotional Functioning: Change at C3D1 (n=117, 260)	4.5 (± 19.1)	2.3 (± 21.6)		
Emotional Functioning: Change at C4D1 (n=100, 231)	4.5 (± 18.5)	2.6 (± 19.7)		
Emotional Functioning: Change at C5D1 (n=76, 207)	5.2 (± 20.1)	-0.4 (± 21.8)		
Emotional Functioning: Change at C6D1 (n=66, 171)	2.1 (± 20.5)	2.4 (± 21.6)		
Emotional Functioning: Change at C7D1 (n=58, 145)	5.3 (± 20.7)	2.8 (± 19.7)		
Fatigue: Baseline (n=160, 312)	30.8 (± 22.5)	30.8 (± 22.0)		
Fatigue: Change at C2D1 (n=147, 292)	2.0 (± 19.2)	-0.5 (± 18.8)		
Fatigue: Change at C3D1 (n=117, 260)	-1.5 (± 19.5)	1.8 (± 21.5)		
Fatigue: Change at C4D1 (n=100, 231)	-0.2 (± 19.1)	2.4 (± 21.9)		
Fatigue: Change at C5D1 (n=76, 207)	-0.1 (± 20.8)	2.8 (± 20.4)		
Fatigue: Change at C6D1 (n=66, 171)	3.3 (± 20.0)	2.4 (± 20.5)		
Fatigue: Change at C7D1 (n=58, 145)	1.0 (± 20.0)	1.8 (± 20.5)		
Financial Difficulties: Baseline (n=160, 310)	18.5 (± 25.8)	19.2 (± 27.1)		
Financial Difficulties: Change at C2D1 (n=147, 287)	-1.1 (± 20.4)	-2.8 (± 21.4)		
Financial Difficulties: Change at C3D1 (n=117, 258)	-0.9 (± 24.9)	-1.6 (± 24.4)		
Financial Difficulties: Change at C4D1 (n=100, 230)	0.7 (± 25.1)	-0.3 (± 23.7)		
Financial Difficulties: Change at C5D1 (n=76, 205)	-0.4 (± 28.0)	0.3 (± 24.9)		
Financial Difficulties: Change at C6D1 (n=66, 169)	5.6 (± 30.1)	0.4 (± 23.6)		
Financial Difficulties: Change at C7D1 (n=58, 143)	-0.6 (± 26.1)	2.1 (± 23.1)		
Global Health Status/QoL: Baseline (n=160, 311)	65.2 (± 18.4)	67.4 (± 20.3)		
Global Health Status/QoL: Change at C2D1 (n=147, 291)	-0.1 (± 16.7)	1.0 (± 19.9)		

Global Health Status/QoL: Change at C3D1 (n=117,259)	-1.0 (± 18.5)	-1.5 (± 20.9)		
Global Health Status/QoL: Change at C4D1 (n=100,230)	-1.5 (± 18.6)	-1.6 (± 20.3)		
Global Health Status/QoL: Change at C5D1 (n=76,207)	0.3 (± 19.9)	-2.8 (± 20.3)		
Global Health Status/QoL: Change at C6D1 (n=66,171)	-1.6 (± 18.6)	-3.4 (± 19.5)		
Global Health Status/QoL: Change at C7D1 (n=58,145)	-1.1 (± 18.9)	-1.0 (± 18.9)		
Insomnia: Baseline (n=160, 311)	26.0 (± 27.6)	26.5 (± 27.7)		
Insomnia: Change at C2D1 (n=146, 289)	-0.9 (± 24.4)	-3.8 (± 23.7)		
Insomnia: Change at C3D1 (n=117, 260)	-3.4 (± 30.1)	-4.1 (± 26.4)		
Insomnia: Change at C4D1 (n=100, 231)	-4.0 (± 28.9)	-1.0 (± 26.8)		
Insomnia: Change at C5D1 (n=76, 206)	-0.4 (± 29.1)	-3.9 (± 25.6)		
Insomnia: Change at C6D1 (n=66, 170)	-2.0 (± 30.3)	-2.4 (± 28.2)		
Insomnia: Change at C7D1 (n=57, 145)	-4.1 (± 28.2)	-1.8 (± 27.2)		
Nausea/Vomiting: Baseline (n=160, 312)	5.9 (± 13.4)	6.7 (± 13.7)		
Nausea/Vomiting: Change at C2D1 (n=147, 292)	0.1 (± 11.9)	1.6 (± 18.1)		
Nausea/Vomiting: Change at C3D1 (n=117, 260)	0.7 (± 15.2)	2.2 (± 17.6)		
Nausea/Vomiting: Change at C4D1 (n=100, 231)	0.3 (± 17.9)	2.3 (± 18.6)		
Nausea/Vomiting: Change at C5D1 (n=76, 207)	-1.1 (± 18.3)	0.5 (± 15.4)		
Nausea/Vomiting: Change at C6D1 (n=66, 171)	1.5 (± 18.0)	-0.6 (± 15.9)		
Nausea/Vomiting: Change at C7D1 (n=58, 145)	2.6 (± 15.5)	2.2 (± 18.8)		
Pain: Baseline (n=160, 312)	28.0 (± 25.4)	27.1 (± 24.9)		
Pain: Change at C2D1 (n=147, 292)	-0.2 (± 24.0)	-5.0 (± 20.8)		
Pain: Change at C3D1 (n=117, 260)	-3.7 (± 23.3)	-3.5 (± 22.6)		
Pain: Change at C4D1 (n=100, 231)	-3.2 (± 24.7)	-1.7 (± 24.2)		
Pain: Change at C5D1 (n=76, 207)	-3.3 (± 24.2)	-4.3 (± 22.9)		
Pain: Change at C6D1 (n=66, 171)	-1.0 (± 23.0)	-2.2 (± 22.5)		
Pain: Change at C7D1 (n=58, 145)	0.3 (± 23.5)	-4.4 (± 19.8)		
Physical Functioning: Baseline (n=160, 311)	76.7 (± 19.9)	78.4 (± 18.8)		
Physical Functioning: Change at C2D1 (n=147, 292)	-1.1 (± 13.4)	1.6 (± 12.7)		
Physical Functioning: Change at C3D1 (n=117, 260)	2.0 (± 14.1)	0.8 (± 15.7)		
Physical Functioning: Change at C4D1 (n=100, 231)	1.5 (± 16.1)	0.3 (± 15.7)		
Physical Functioning: Change at C5D1 (n=76, 207)	2.0 (± 17.7)	1.0 (± 13.5)		
Physical Functioning: Change at C6D1 (n=66, 171)	0.9 (± 18.4)	1.1 (± 14.9)		
Physical Functioning: Change at C7D1 (n=58, 145)	1.6 (± 16.2)	0.6 (± 14.2)		
Role Functioning: Baseline (n=160, 312)	79.1 (± 24.6)	78.7 (± 24.0)		
Role Functioning: Change at C2D1 (n=147, 292)	-2.0 (± 19.3)	1.7 (± 21.5)		
Role Functioning: Change at C3D1 (n=117, 260)	-0.4 (± 23.4)	-1.0 (± 23.9)		

Role Functioning: Change at C4D1 (n=100, 231)	0.3 (± 23.0)	0.4 (± 24.2)		
Role Functioning: Change at C5D1 (n=76, 207)	1.8 (± 22.5)	-1.6 (± 21.6)		
Role Functioning: Change at C6D1 (n=66, 171)	-1.3 (± 23.8)	-1.6 (± 23.4)		
Role Functioning: Change at C7D1 (n=58, 145)	-0.3 (± 22.6)	0.0 (± 22.9)		
Social Functioning: Baseline (n=160, 312)	83.2 (± 21.8)	81.2 (± 23.1)		
Social Functioning: Change at C2D1 (n=147, 292)	-0.8 (± 19.9)	2.7 (± 20.0)		
Social Functioning: Change at C3D1 (n=117, 259)	1.3 (± 21.9)	-0.8 (± 23.2)		
Social Functioning: Change at C4D1 (n=100, 231)	1.8 (± 18.2)	-0.5 (± 21.3)		
Social Functioning: Change at C5D1 (n=76, 207)	0.9 (± 19.4)	-1.0 (± 23.3)		
Social Functioning: Change at C6D1 (n=66, 170)	-0.8 (± 20.1)	-1.6 (± 23.4)		
Social Functioning: Change at C7D1 (n=58, 145)	0.6 (± 21.2)	0.1 (± 19.7)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Modified EORTC Quality of Life Questionnaire Breast Cancer Module 23 (QLQ-BR23) Score

End point title	Change From Baseline in Modified EORTC Quality of Life Questionnaire Breast Cancer Module 23 (QLQ-BR23) Score
-----------------	---

End point description:

EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of functional scales (body image, sexual enjoyment, sexual functioning, future perspective [FP]) and symptom scales (systemic side effects [SE], upset by hair loss, arm symptoms, breast symptoms). Questions used a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to a 0-100 scale. Higher scores for the functional scales indicated a higher/better level of functioning/healthy functioning. Higher scores for the symptom scales indicated worse symptoms. Randomised subjects with PIK3CA-mutant tumors, regardless of whether they received any amount of study treatment. "n" is the number of subjects with data available for analysis at given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, C2D1 up to C7D1 (each cycle=28 days)

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	340		
Units: score on a scale				
arithmetic mean (standard deviation)				
Arm Symptoms: Baseline (n=152, 304)	15.5 (± 18.8)	19.3 (± 21.1)		

Arm Symptoms: Change at C2D1 (n=140, 282)	0.1 (± 17.4)	-5.4 (± 15.6)		
Arm Symptoms: Change at C3D1 (n=111, 250)	-0.7 (± 19.5)	-6.1 (± 17.4)		
Arm Symptoms: Change at C4D1 (n=95, 219)	-1.4 (± 21.9)	-5.8 (± 15.8)		
Arm Symptoms: Change at C5D1 (n=72, 203)	0.8 (± 17.0)	-6.6 (± 15.7)		
Arm Symptoms: Change at C6D1 (n=63, 167)	1.1 (± 20.8)	-5.0 (± 18.5)		
Arm Symptoms: Change at C7D1 (n=57, 140)	-1.2 (± 19.7)	-6.0 (± 15.2)		
Body Image: Baseline (n=149, 300)	82.0 (± 21.7)	80.8 (± 22.5)		
Body Image: Change at C2D1 (n=135, 276)	1.8 (± 14.9)	1.5 (± 16.5)		
Body Image: Change at C3D1 (n=106, 242)	1.6 (± 18.0)	1.1 (± 20.6)		
Body Image: Change at C4D1 (n=92, 214)	1.1 (± 17.8)	1.8 (± 20.6)		
Body Image: Change at C5D1 (n=68, 198)	0.2 (± 19.5)	0.0 (± 17.5)		
Body Image: Change at C6D1 (n=60, 164)	1.1 (± 21.0)	0.4 (± 18.2)		
Body Image: Change at C7D1 (n=54, 137)	5.6 (± 18.8)	-0.3 (± 18.2)		
Breast Symptoms: Baseline (n=151, 304)	8.7 (± 14.6)	11.0 (± 14.1)		
Breast Symptoms: Change at C2D1 (n=139, 282)	0.0 (± 13.7)	-3.0 (± 11.8)		
Breast Symptoms: Change at C3D1 (n=112, 250)	-0.8 (± 13.3)	-3.5 (± 11.6)		
Breast Symptoms: Change at C4D1 (n=95, 220)	0.1 (± 14.2)	-3.0 (± 11.8)		
Breast Symptoms: Change at C5D1 (n=72, 203)	-0.9 (± 14.5)	-2.0 (± 11.7)		
Breast Symptoms: Change at C6D1 (n=63, 167)	1.7 (± 16.0)	-2.0 (± 12.9)		
Breast Symptoms: Change at C7D1 (n=57, 140)	0.3 (± 12.6)	-3.2 (± 13.1)		
Future Perspective: Baseline (n=152, 303)	47.4 (± 31.5)	47.3 (± 29.6)		
Future Perspective: Change at C2D1 (n=139, 281)	3.4 (± 30.1)	6.8 (± 27.4)		
Future Perspective: Change at C3D1 (n=111, 247)	5.1 (± 29.5)	4.3 (± 30.5)		
Future Perspective: Change at C4D1 (n=95, 220)	6.0 (± 30.7)	7.0 (± 29.2)		
Future Perspective: Change at C5D1 (n=72, 202)	6.0 (± 30.3)	5.0 (± 26.8)		
Future Perspective: Change at C6D1 (n=63, 167)	6.9 (± 28.8)	9.0 (± 31.4)		
Future Perspective: Change at C7D1 (n=57, 139)	12.9 (± 29.4)	7.0 (± 30.2)		
Sexual Enjoyment: Baseline (n=27, 61)	51.9 (± 26.7)	62.8 (± 26.6)		
Sexual Enjoyment: Change at C2D1 (n=17, 35)	5.9 (± 21.2)	0.0 (± 18.1)		
Sexual Enjoyment: Change at C3D1 (n=14, 26)	4.8 (± 22.1)	1.3 (± 24.0)		
Sexual Enjoyment: Change at C4D1 (n=8, 24)	-8.3 (± 15.4)	4.2 (± 24.7)		
Sexual Enjoyment: Change at C5D1 (n=7, 26)	-4.8 (± 23.0)	2.6 (± 29.7)		

Sexual Enjoyment: Change at C6D1 (n=5, 17)	-6.7 (± 14.9)	-5.9 (± 24.3)		
Sexual Enjoyment: Change at C7D1 (n=5, 14)	-13.3 (± 29.8)	9.5 (± 20.4)		
Sexual Functioning: Baseline (n=142, 291)	89.6 (± 17.9)	89.9 (± 17.3)		
Sexual Functioning: Change at C2D1 (n=126, 267)	1.6 (± 11.0)	1.5 (± 14.2)		
Sexual Functioning: Change at C3D1 (n=98, 235)	1.4 (± 10.6)	1.8 (± 15.6)		
Sexual Functioning: Change at C4D1 (n=86, 203)	1.9 (± 15.4)	1.6 (± 13.9)		
Sexual Functioning: Change at C5D1 (n=63, 186)	-0.8 (± 20.6)	2.6 (± 15.1)		
Sexual Functioning: Change at C6D1 (n=55, 156)	2.4 (± 18.8)	2.7 (± 15.0)		
Sexual Functioning: Change at C7D1 (n=49, 132)	2.7 (± 18.1)	2.3 (± 15.7)		
Systematic Therapy SEs: Baseline (n=152, 304)	15.7 (± 14.2)	14.7 (± 12.0)		
Systematic Therapy SEs:Change at C2D1 (n=140, 282)	0.2 (± 11.4)	2.5 (± 11.0)		
Systematic Therapy SEs:Change at C3D1 (n=112, 250)	1.2 (± 14.4)	4.0 (± 13.6)		
Systematic Therapy SEs:Change at C4D1 (n=95, 220)	1.5 (± 13.2)	4.0 (± 13.3)		
Systematic Therapy SEs:Change at C5D1 (n=72, 203)	2.4 (± 13.8)	5.5 (± 14.1)		
Systematic Therapy SEs:Change at C6D1 (n=63, 167)	2.9 (± 15.2)	5.7 (± 15.6)		
Systematic Therapy SEs:Change at C7D1 (n=57, 140)	3.5 (± 16.7)	4.8 (± 15.0)		
Upset by Hair Loss: Baseline (n=33, 63)	23.2 (± 28.2)	27.0 (± 29.2)		
Upset by Hair Loss: Change at C2D1 (n=14, 31)	-11.9 (± 28.1)	-4.3 (± 22.3)		
Upset by Hair Loss: Change at C3D1 (n=13, 29)	-7.7 (± 30.9)	0.0 (± 26.7)		
Upset by Hair Loss: Change at C4D1 (n=13, 27)	2.6 (± 16.5)	0.0 (± 29.2)		
Upset by Hair Loss: Change at C5D1 (n=8, 28)	0.0 (± 25.2)	10.7 (± 27.3)		
Upset by Hair Loss: Change at C6D1 (n=6, 26)	11.1 (± 27.2)	16.7 (± 30.2)		
Upset by Hair Loss: Change at C7D1 (n=8, 26)	4.2 (± 11.8)	14.1 (± 32.9)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects with Objective Response (PR plus CR), as Assessed Using RECIST v.1.1 at Final Analysis

End point title	Percentage of Subjects with Objective Response (PR plus CR), as Assessed Using RECIST v.1.1 at Final Analysis
-----------------	---

End point description:

PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalisation of tumor marker levels (as applicable to non-target lesions). Randomised subjects with

PIK3CA-mutant tumors and measurable disease at baseline, regardless of whether they received any amount of study treatment. Number of subjects analysed is the number of subjects with data available for analysis at given time point.

End point type	Secondary
End point timeframe:	
From randomisation until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years)	

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134	264		
Units: percentage of subjects				
number (confidence interval 95%)	13.4 (8.2 to 20.2)	31.1 (25.5 to 36.8)		

## Statistical analyses

Statistical analysis title	Taselisib+Fulvestrant vs Placebo+Fulvestrant
Comparison groups	Placebo+Fulvestrant v Taselisib+Fulvestrant
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.7
upper limit	5.4

## Secondary: OS at Final Analysis

End point title	OS at Final Analysis
End point description:	
OS was defined as the time from the date of randomisation to the date of death due to any cause. Randomised subjects with PIK3CA-mutant tumors, regardless of whether they received any amount of study treatment. Number of subjects analysed is the number of subjects with data available for analysis at given time point. 99999 represents that the upper limit of confidence interval was not estimable due to the low number of subjects with events.	
End point type	Secondary
End point timeframe:	
From randomisation up to death from any cause (up to approximately 6.2 years)	

<b>End point values</b>	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	340		
Units: months				
median (confidence interval 95%)	27.93 (24.38 to 99999)	27.79 (24.25 to 33.35)		

## Statistical analyses

<b>Statistical analysis title</b>	Taselisib+Fulvestrant vs Placebo+Fulvestrant
Comparison groups	Placebo+Fulvestrant v Taselisib+Fulvestrant
Number of subjects included in analysis	516
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9974
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.75
upper limit	1.33

## Secondary: Percentage of Subjects with Clinical Benefit, as Assessed According to RECIST v1.1 at Final Analysis

End point title	Percentage of Subjects with Clinical Benefit, as Assessed According to RECIST v1.1 at Final Analysis
End point description:	Clinical benefit:objective response (PR+CR),or no disease progression lasting for more than or equal to (>/=) 24 weeks since randomisation.PR:at least a 30% decrease in sum of diameters of target lesions,taking as reference baseline sum of diameters.CR:disappearance of all target and non-target lesions and normalisation of tumor marker levels.Disease progression:at least a 20% increase in sum of diameters of target lesions,taking as reference smallest sum on study,including baseline.In addition to relative increase of 20%,sum must also demonstrate absolute increase of at least 5 mm.For non-target lesions,disease progression:unequivocal progression of existing lesions.Appearance of one or more new lesions was also considered progression.Randomised subjects with PIK3CA-mutant tumors and measurable disease at baseline,regardless of whether they received any amount of study treatment.Number of subjects analysed is number of subjects with data available at given time point.
End point type	Secondary
End point timeframe:	From randomisation until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years)

<b>End point values</b>	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	134	264		
Units: percentage of subjects				
number (confidence interval 95%)	45.5 (37.2 to 54.3)	59.5 (53.6 to 65.4)		

## Statistical analyses

<b>Statistical analysis title</b>	Taselisib+Fulvestrant vs Placebo+Fulvestrant
Comparison groups	Placebo+Fulvestrant v Taselisib+Fulvestrant
Number of subjects included in analysis	398
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.2
upper limit	3

## Secondary: DOR as Assessed by Investigator Using RECIST v1.1 at Final Analysis

End point title	DOR as Assessed by Investigator Using RECIST v1.1 at Final Analysis
-----------------	---

### End point description:

DOR:time from first tumor assessment for objective response to first documented disease progression or death due to any cause, whichever occurred first. CR:disappearance of all target and non-target lesions and normalisation of tumor marker levels.PR:at least a 30% decrease in the sum of diameters of target lesions,taking as reference baseline sum of diameters. Disease progression:at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline.For non-target lesions, disease progression:unequivocal progression of existing lesions.Appearance of one or more new lesions was also considered progression.Randomised subjects with PIK3CA-mutant tumors and measurable disease at baseline, regardless of whether they received any amount of study treatment. Number analysed:number of subjects with data available for analysis at given timepoint.

End point type	Secondary
----------------	-----------

### End point timeframe:

Time from the first occurrence of a documented objective response to the time of the first documented disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years)



End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18	82		
Units: months				
median (confidence interval 95%)	7.39 (4.67 to 23.95)	8.97 (7.36 to 12.91)		

## Statistical analyses

Statistical analysis title	Taselisib+Fulvestrant vs Placebo+Fulvestrant
Comparison groups	Placebo+Fulvestrant v Taselisib+Fulvestrant
Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8286
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.51
upper limit	2.35

## Secondary: PFS as Assessed by BICR Using RECIST v1.1 at Final Analysis

End point title	PFS as Assessed by BICR Using RECIST v1.1 at Final Analysis
-----------------	---

### End point description:

PFS was defined as the time from randomisation to disease progression as determined by BICR with the use of RECIST v1.1 or death due to any cause, whichever occurred earlier. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, disease progression was defined as unequivocal progression of existing lesions. The appearance of one or more new lesions was also considered progression. Randomised subjects with PIK3CA-mutant tumors, regardless of whether they received any amount of study treatment. Number of subjects analysed is the number of subjects with data available for analysis at given time point.

End point type	Secondary
----------------	-----------

### End point timeframe:

From randomisation until the first occurrence of disease progression or death from any cause, whichever occurs earlier (up to approximately 6.2 years)

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	176	340		
Units: months				
median (confidence interval 95%)	5.55 (3.68 to 9.30)	9.20 (8.15 to 10.87)		

## Statistical analyses

Statistical analysis title	Taselisib+Fulvestrant vs Placebo+Fulvestrant
Comparison groups	Placebo+Fulvestrant v Taselisib+Fulvestrant
Number of subjects included in analysis	516
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0095
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	0.92

## Secondary: Percentage of Subjects with AEs at Final Analysis

End point title	Percentage of Subjects with AEs at Final Analysis
End point description:	An AE was any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The safety-evaluable population included all randomised subjects who received at least one dose of taselisib or placebo or fulvestrant. Number of subjects analysed is the number of subjects with data available for analysis at given time point.
End point type	Secondary
End point timeframe:	From randomisation up to approximately 6.2 years

End point values	Placebo+Fulvestrant	Taselisib+Fulvestrant		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	213	416		
Units: percentage of subjects				
number (not applicable)	91.1	97.1		

## Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From randomization up to the end of study, approximately 6.2 years

Adverse event reporting additional description:

The safety-evaluable population included all randomized participants who received at least one dose of tasisib, placebo or fulvestrant regardless of the PIK3CA-mutation status of their tumors with participants allocated to the treatment arm associated with the regimen actually received.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

### Reporting groups

Reporting group title	Taselisib+Fulvestrant
-----------------------	-----------------------

Reporting group description:

Subjects received tasisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.

Reporting group title	Placebo+Fulvestrant
-----------------------	---------------------

Reporting group description:

Subjects received tasisib-matching placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.

Serious adverse events	Taselisib+Fulvestrant	Placebo+Fulvestrant	
Total subjects affected by serious adverse events			
subjects affected / exposed	154 / 416 (37.02%)	23 / 213 (10.80%)	
number of deaths (all causes)	197	98	
number of deaths resulting from adverse events	2	1	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
HEPATOCELLULAR CARCINOMA			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
INTRACRANIAL TUMOUR			
HAEMORRHAGE			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			

EMBOLISM			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SHOCK			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HYPERTENSION			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
EMBOLISM VENOUS			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
CHILLS			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PYREXIA			
subjects affected / exposed	3 / 416 (0.72%)	2 / 213 (0.94%)	
occurrences causally related to treatment / all	1 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
PAIN			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHEST DISCOMFORT			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

FATIGUE			
subjects affected / exposed	2 / 416 (0.48%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	1 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ASTHENIA			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHEST PAIN			
subjects affected / exposed	3 / 416 (0.72%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SWELLING FACE			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
MUCOSAL INFLAMMATION			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEATH			
subjects affected / exposed	3 / 416 (0.72%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 3	0 / 1	
Immune system disorders			
ANAPHYLACTIC SHOCK			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
INTERMENSTRUAL BLEEDING			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Respiratory, thoracic and mediastinal disorders			
INTERSTITIAL LUNG DISEASE			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY OEDEMA			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PLEURAL EFFUSION			
subjects affected / exposed	1 / 416 (0.24%)	2 / 213 (0.94%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
DYSPNOEA			
subjects affected / exposed	1 / 416 (0.24%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMONITIS			
subjects affected / exposed	10 / 416 (2.40%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	10 / 10	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
ACUTE RESPIRATORY DISTRESS SYNDROME			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
ACUTE RESPIRATORY FAILURE			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
PLEURITIC PAIN			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

RESPIRATORY FAILURE			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PNEUMOTHORAX			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PULMONARY EMBOLISM			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COUGH			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
CONFUSIONAL STATE			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MENTAL STATUS CHANGES			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
ASPARTATE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	1 / 416 (0.24%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
WHITE BLOOD CELL COUNT DECREASED			



subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ALANINE AMINOTRANSFERASE INCREASED			
subjects affected / exposed	2 / 416 (0.48%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
HIP FRACTURE			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
WRIST FRACTURE			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
JOINT DISLOCATION			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TOXICITY TO VARIOUS AGENTS			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CLAVICLE FRACTURE			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
FALL			
subjects affected / exposed	2 / 416 (0.48%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEMORAL NECK FRACTURE			

subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
FEMUR FRACTURE			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
ATRIAL FIBRILLATION			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CARDIAC FAILURE CONGESTIVE			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SUPRAVENTRICULAR TACHYCARDIA			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
MYOCARDIAL INFARCTION			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Nervous system disorders			
HEADACHE			
subjects affected / exposed	3 / 416 (0.72%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TRANSIENT ISCHAEMIC ATTACK			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TRIGEMINAL NEURALGIA			

subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>HYPOAESTHESIA</b>			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CEREBRAL HAEMATOMA</b>			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>FACIAL PARALYSIS</b>			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>CEREBROVASCULAR ACCIDENT</b>			
subjects affected / exposed	1 / 416 (0.24%)	2 / 213 (0.94%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>VITH NERVE PARALYSIS</b>			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
<b>ANAEMIA</b>			
subjects affected / exposed	2 / 416 (0.48%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	1 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>PANCYTOPENIA</b>			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			

DYSPHAGIA			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VOMITING			
subjects affected / exposed	4 / 416 (0.96%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	2 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTRITIS			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PANCREATITIS ACUTE			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
STOMATITIS			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTRIC ULCER			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABDOMINAL PAIN UPPER			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENTEROCOLITIS			
subjects affected / exposed	3 / 416 (0.72%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	3 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COLITIS			

subjects affected / exposed	16 / 416 (3.85%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	17 / 17	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ENTERITIS			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIARRHOEA			
subjects affected / exposed	37 / 416 (8.89%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	36 / 40	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
OESOPHAGEAL ULCER			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SMALL INTESTINAL OBSTRUCTION			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
NAUSEA			
subjects affected / exposed	4 / 416 (0.96%)	2 / 213 (0.94%)	
occurrences causally related to treatment / all	3 / 5	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
ABDOMINAL PAIN			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PANCREATITIS			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ALCOHOLIC PANCREATITIS			

subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
OESOPHAGITIS			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DYSPEPSIA			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
CHOLECYSTITIS ACUTE			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLELITHIASIS			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HEPATOTOXICITY			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Skin and subcutaneous tissue disorders			
RASH			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
TOXIC SKIN ERUPTION			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DRUG ERUPTION			

subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RASH MACULO-PAPULAR			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
PRURITUS			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
ACUTE KIDNEY INJURY			
subjects affected / exposed	4 / 416 (0.96%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 4	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
HAEMATURIA			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
URETEROLITHIASIS			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RENAL FAILURE			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
MUSCLE SPASMS			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

MUSCULAR WEAKNESS			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
BACK PAIN			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COCCYDYNIA			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
OSTEONECROSIS OF JAW			
subjects affected / exposed	0 / 416 (0.00%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
RHABDOMYOLYSIS			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
ARTHRALGIA			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
ENTEROCOLITIS INFECTIOUS			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
BRONCHITIS			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROENTERITIS VIRAL			



subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
LOWER RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CYSTITIS ESCHERICHIA			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
UROSEPSIS			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
HERPES ZOSTER			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CHOLERA			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SKIN INFECTION			
subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SEPSIS			
subjects affected / exposed	5 / 416 (1.20%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
PNEUMONIA			

subjects affected / exposed	10 / 416 (2.40%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	4 / 10	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
ATYPICAL MYCOBACTERIAL PNEUMONIA			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CLOSTRIDIUM DIFFICILE COLITIS			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
GASTROENTERITIS			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DIARRHOEA INFECTIOUS			
subjects affected / exposed	3 / 416 (0.72%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	2 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
SEPTIC ARTHRITIS STAPHYLOCOCCAL			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
RESPIRATORY TRACT INFECTION			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
APPENDICITIS PERFORATED			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
CELLULITIS			

subjects affected / exposed	2 / 416 (0.48%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
URINARY TRACT INFECTION			
subjects affected / exposed	3 / 416 (0.72%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
VIRAL INFECTION			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
HYPERGLYCAEMIA			
subjects affected / exposed	7 / 416 (1.68%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	7 / 7	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
DEHYDRATION			
subjects affected / exposed	7 / 416 (1.68%)	1 / 213 (0.47%)	
occurrences causally related to treatment / all	5 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
DECREASED APPETITE			
subjects affected / exposed	1 / 416 (0.24%)	0 / 213 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Taselisib+Fulvestrant	Placebo+Fulvestrant	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	396 / 416 (95.19%)	183 / 213 (85.92%)	
Investigations			
BLOOD CREATININE INCREASED			
subjects affected / exposed	25 / 416 (6.01%)	6 / 213 (2.82%)	
occurrences (all)	28	7	

BLOOD ALKALINE PHOSPHATASE INCREASED	subjects affected / exposed	15 / 416 (3.61%)	12 / 213 (5.63%)	
	occurrences (all)	17	12	
ASPARTATE AMINOTRANSFERASE INCREASED	subjects affected / exposed	35 / 416 (8.41%)	15 / 213 (7.04%)	
	occurrences (all)	47	19	
WEIGHT DECREASED	subjects affected / exposed	42 / 416 (10.10%)	6 / 213 (2.82%)	
	occurrences (all)	50	6	
ALANINE AMINOTRANSFERASE INCREASED	subjects affected / exposed	36 / 416 (8.65%)	9 / 213 (4.23%)	
	occurrences (all)	47	13	
Vascular disorders				
HOT FLUSH	subjects affected / exposed	24 / 416 (5.77%)	27 / 213 (12.68%)	
	occurrences (all)	26	27	
HYPERTENSION	subjects affected / exposed	33 / 416 (7.93%)	11 / 213 (5.16%)	
	occurrences (all)	42	16	
Nervous system disorders				
DYSGEUSIA	subjects affected / exposed	36 / 416 (8.65%)	5 / 213 (2.35%)	
	occurrences (all)	41	5	
HEADACHE	subjects affected / exposed	88 / 416 (21.15%)	27 / 213 (12.68%)	
	occurrences (all)	122	38	
DIZZINESS	subjects affected / exposed	46 / 416 (11.06%)	18 / 213 (8.45%)	
	occurrences (all)	58	23	
General disorders and administration site conditions				
PYREXIA	subjects affected / exposed	48 / 416 (11.54%)	9 / 213 (4.23%)	
	occurrences (all)	61	10	
FATIGUE				

subjects affected / exposed	105 / 416 (25.24%)	40 / 213 (18.78%)	
occurrences (all)	134	51	
MUCOSAL INFLAMMATION			
subjects affected / exposed	44 / 416 (10.58%)	11 / 213 (5.16%)	
occurrences (all)	67	15	
ASTHENIA			
subjects affected / exposed	77 / 416 (18.51%)	40 / 213 (18.78%)	
occurrences (all)	104	65	
OEDEMA PERIPHERAL			
subjects affected / exposed	19 / 416 (4.57%)	11 / 213 (5.16%)	
occurrences (all)	25	13	
Blood and lymphatic system disorders			
NEUTROPENIA			
subjects affected / exposed	28 / 416 (6.73%)	9 / 213 (4.23%)	
occurrences (all)	39	12	
ANAEMIA			
subjects affected / exposed	44 / 416 (10.58%)	20 / 213 (9.39%)	
occurrences (all)	62	23	
Gastrointestinal disorders			
GASTROESOPHAGEAL REFLUX DISEASE			
subjects affected / exposed	23 / 416 (5.53%)	4 / 213 (1.88%)	
occurrences (all)	25	4	
CONSTIPATION			
subjects affected / exposed	32 / 416 (7.69%)	32 / 213 (15.02%)	
occurrences (all)	36	36	
VOMITING			
subjects affected / exposed	86 / 416 (20.67%)	25 / 213 (11.74%)	
occurrences (all)	116	41	
DIARRHOEA			
subjects affected / exposed	255 / 416 (61.30%)	45 / 213 (21.13%)	
occurrences (all)	602	76	
DRY MOUTH			
subjects affected / exposed	55 / 416 (13.22%)	18 / 213 (8.45%)	
occurrences (all)	62	19	
STOMATITIS			

subjects affected / exposed	87 / 416 (20.91%)	8 / 213 (3.76%)	
occurrences (all)	139	11	
NAUSEA			
subjects affected / exposed	154 / 416 (37.02%)	54 / 213 (25.35%)	
occurrences (all)	233	71	
DYSPEPSIA			
subjects affected / exposed	32 / 416 (7.69%)	5 / 213 (2.35%)	
occurrences (all)	51	5	
ABDOMINAL PAIN UPPER			
subjects affected / exposed	31 / 416 (7.45%)	8 / 213 (3.76%)	
occurrences (all)	35	8	
ABDOMINAL PAIN			
subjects affected / exposed	55 / 416 (13.22%)	20 / 213 (9.39%)	
occurrences (all)	67	25	
Respiratory, thoracic and mediastinal disorders			
DYSPNOEA			
subjects affected / exposed	50 / 416 (12.02%)	17 / 213 (7.98%)	
occurrences (all)	53	17	
COUGH			
subjects affected / exposed	64 / 416 (15.38%)	34 / 213 (15.96%)	
occurrences (all)	78	41	
Skin and subcutaneous tissue disorders			
RASH			
subjects affected / exposed	80 / 416 (19.23%)	17 / 213 (7.98%)	
occurrences (all)	116	24	
DRY SKIN			
subjects affected / exposed	37 / 416 (8.89%)	10 / 213 (4.69%)	
occurrences (all)	40	10	
PRURITUS			
subjects affected / exposed	52 / 416 (12.50%)	18 / 213 (8.45%)	
occurrences (all)	75	28	
ALOPECIA			
subjects affected / exposed	50 / 416 (12.02%)	6 / 213 (2.82%)	
occurrences (all)	53	6	
Psychiatric disorders			

INSOMNIA subjects affected / exposed occurrences (all)	37 / 416 (8.89%) 40	18 / 213 (8.45%) 19	
Musculoskeletal and connective tissue disorders MUSCLE SPASMS subjects affected / exposed occurrences (all)  BACK PAIN subjects affected / exposed occurrences (all)  BONE PAIN subjects affected / exposed occurrences (all)  ARTHRALGIA subjects affected / exposed occurrences (all)  MYALGIA subjects affected / exposed occurrences (all)  PAIN IN EXTREMITY subjects affected / exposed occurrences (all)	32 / 416 (7.69%) 34  62 / 416 (14.90%) 82  24 / 416 (5.77%) 26  69 / 416 (16.59%) 95  36 / 416 (8.65%) 42  33 / 416 (7.93%) 42	6 / 213 (2.82%) 8  28 / 213 (13.15%) 32  17 / 213 (7.98%) 19  35 / 213 (16.43%) 50  14 / 213 (6.57%) 14  19 / 213 (8.92%) 27	
Infections and infestations UPPER RESPIRATORY TRACT INFECTION subjects affected / exposed occurrences (all)  URINARY TRACT INFECTION subjects affected / exposed occurrences (all)	33 / 416 (7.93%) 41  38 / 416 (9.13%) 50	11 / 213 (5.16%) 17  9 / 213 (4.23%) 10	
Metabolism and nutrition disorders HYPERGLYCAEMIA subjects affected / exposed occurrences (all)  HYPOKALAEMIA subjects affected / exposed occurrences (all)	166 / 416 (39.90%) 233  31 / 416 (7.45%) 37	21 / 213 (9.86%) 26  2 / 213 (0.94%) 2	

DECREASED APPETITE			
subjects affected / exposed	119 / 416 (28.61%)	23 / 213 (10.80%)	
occurrences (all)	136	25	



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 December 2015	The changes in Protocol v2 were as follows: The study design section was updated. Now, all subjects who discontinued study treatment were followed for OS and subsequent anti-cancer therapies, not only those who discontinued study treatment due to disease progression. The text was also updated to clarify that only subjects who discontinued taselisib/placebo for toxicity could continue single agent fulvestrant at the discretion of the investigator while those who discontinued fulvestrant for an AE, albeit rare, should discuss continuation of single agent taselisib/placebo with the Medical Monitor. The biomarker section was updated to clarify the analysis of optional post-progression biopsies and sharing of the resulting molecular report with investigator who may then share the data with the subject (if the subject agreed). Subjects who discontinue study treatment for reasons other than disease progression will continue to undergo tumor assessments until progressive disease (PD), even if a subject initiates anti-cancer therapy subsequent to study drug discontinuation. An update was made to clarify corticosteroid treatment for Grade 3 diarrhoea or colitis. An update was made for clarification of the pneumonitis guidelines related to local clinical practice. A footnote was added to clarify for Grade 1 or 2 hyperglycemia that increases in anti-hyperglycemic medications only applied to subjects who initiated these after randomisation since subjects with diabetes requiring anti-hyperglycemic medications were not eligible. Updates were made to point to specific management guidelines for subjects who experienced changes in blood counts or showed signs of infections if deemed clinically appropriate by the investigator. An update was made regarding additional supporting data sponsor may request for certain AEs. A clarification was included to mention that the study used electronic patient-reported outcome (ePRO) devices and no paper questionnaires.
15 January 2017	The changes in Protocol v3 were as follows: The testing hierarchy of the secondary endpoints was changed to ORR first followed by OS after a statistically significant investigator-assessed PFS. OS was still formally tested if both investigator-assessed PFS and ORR reached their significance level. A secondary efficacy objective/outcome measure was added: BICR-assessed PFS, which was intended to show that there was no potential bias in the investigator-assessed PFS. CBR was added to the exploratory objectives. The possible addition of a China extension cohort was introduced. After the global enrollment closes, additional Chinese subjects may continue to be recruited into the China extension cohort. A total of up to 150 Chinese subjects with detectable PIK3CA-mutant tumors may be enrolled as part of the global study population and extension cohort combined. An inclusion criterion was added to define the subject population in the China extension cohort to be from the People's Republic of China. Blinding criteria for study personnel on the basis of the results of the interim and final analyses for investigator-assessed PFS was added. Optional post-progression biopsies could still be obtained within approximately 14 days of the start of the new anti-cancer treatment as long as it was deemed safe by the investigator.
15 January 2017	Additional changes in Protocol v3 were as follows: Clarifications of AE management guidelines: For diarrhoea, dose resumption was distinguished for certain cases of infectious diarrhoea; For pneumonitis, infectious work-up was listed as a relevant investigation. An interim efficacy analysis of investigator-assessed PFS was added to enable an earlier assessment of efficacy that could provide subjects with PIK3CA-mutant tumors with earlier access to a potentially effective targeted therapy should the iDMC recommended stopping the study early on the basis of results from the interim analysis for investigator-assessed PFS and should the Sponsor decide to accept the recommendation and obtained regulatory approval. The analysis of CBR was clarified to be performed for subjects with PIK3CA-mutant tumors with measurable disease at baseline as well as regardless of measurable disease at baseline. A time-to-deterioration analysis was included as one of the PRO to assess if there was a difference between the treatment arms.

24 June 2018	The changes in Protocol v4 were as follows: Background and Safety sections were updated with new taselisib adverse drug reactions detected in the primary PFS analysis and with management guidelines for infection. After approximately the end of August 2018, tumor assessments may be conducted per local standard of care because sufficient data have been gathered for these assessments. These include: tumor assessments for subjects who are discontinued from study treatment for reasons other than disease progression and tumor assessments 46 weeks after disease progression, all patient-reported outcomes (PROs), survival and subsequent anti-cancer therapies after study treatment discontinuation, Eastern Cooperative Oncology Group (ECOG) Performance Status, optional post-progression core tumor biopsy and Roche Clinical Repository (RCR) blood samples, plasma samples for pharmacokinetic (PK) and exploratory research, blood samples for next-generation sequencing (NGS) and pharmacogenetic assessment. The independent Data Monitoring Committee (iDMC) will only oversee safety monitoring until the primary PFS analysis has been completed and the Sponsor is unblinded. The end of the global study will be when the last patient, last visit (LPLV) has occurred or safety follow-up is received from the last patient (28 days after the last dose of study drug), whichever occurs later, or when the Sponsor decides to stop the study.
24 June 2018	Additional changes in Protocol v4 were as follows: After approximately the end of August 2018: Unblinding is permitted at the discretion of the investigator or Sponsor because the primary PFS analysis will have been completed, and blinding is no longer required; the list of prohibited therapies requiring Medical Monitor approval to initiate will be reduced, because the primary PFS analysis has been completed and these restrictions are no longer required. Adverse event follow-up will not be done after a subject is no longer being followed for survival because subjects will have been withdrawn from the study at that point. OS follow-up has been limited to one additional analysis because sufficient data have been gathered for this assessment. This additional OS analysis coincides with the originally planned second OS interim analysis.

Notes:

## Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
29 June 2021	The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.	-

Notes:

## Limitations and caveats

None reported